YARW
Yarrow Bioscience Inc
YARW lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
YARW Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
YARW's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
YARW PE Valuation
YARW has no meaningful PE right now: it lost money over the past year.
YARW Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect YARW's losses to shrink, with revenue declining.
YARW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$23.27 | +$21.23 |
| Q1 2026 | -$26.26 | +$22.74 |
| Q4 2025 | -$32.26 | +$14.24 |
| Q3 2023 | -$498.97 | -$111.97 |
| Q2 2023 | -$542.47 | +$69.53 |
| Q1 2023 | -$522.97 | +$305.03 |
| Q4 2022 | -$363.97 | +$914.03 |
| Q3 2022 | -$387.00 | +$216.00 |
YARW lost $23.27 per share over the past year, a smaller loss than the year before.
YARW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $97K | +41% |
| Q1 2026 | $86K | -57% |
| Q4 2025 | $130K | +55% |
| Q3 2025 | $169K | +40% |
| Q2 2025 | $69K | -65% |
| Q1 2025 | $202K | +106% |
| Q4 2024 | $84K | +11% |
| Q3 2024 | $121K | +6.1% |
YARW's revenue is recovering but still below its 2020 peak: $97,000 last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3198% | +7733 points |
| Q1 2026 | -4437% | +116 points |
| Q4 2025 | -4015% | +11188 points |
| Q3 2025 | -4611% | +6208 points |
| Q2 2025 | -10930% | -5680 points |
| Q1 2025 | -4553% | +2978 points |
| Q4 2024 | -15202% | -6213 points |
| Q3 2024 | -10819% | -5351 points |
YARW's operating margin was −3198% last quarter, up 7732 points from the same quarter a year ago.
YARW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$8.8M |
| Q1 2026 | -$4.1M | +$7.4M |
| Q3 2025 | -$7.1M | +$1.4M |
| Q2 2025 | -$10.8M | -$2.3M |
| Q1 2025 | -$11.5M | -$3.5M |
| Q3 2024 | -$8.5M | -$3.4M |
| Q2 2024 | -$8.5M | +$1.1M |
| Q1 2024 | -$8M | -$2.5M |
YARW has burned cash in almost every quarter: −$17M over the past year, against −$39M the year before.
YARW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.6K shares |
| 1 year | +0.3% | +2.8K shares |
| 3 years | +1247% | +794K shares |
| 5 years | +1741% | +811K shares |
| Available history | +12794% | +851K shares |
YARW has 858,000 diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $15,000 |
| Q3 2025 | $7,000 |
YARW Net Leverage
YARW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
YARW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 13.3 | Oversold |
YARW's weekly RSI is 40 (neutral) and its Stochastic is 13 (oversold).
YARW PE vs Healthcare Sector
YARW has no meaningful PE right now: it lost money over the past year.
YARW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.0 | 2% below |
| 20 week MA | $28.4 | 31% below |
| 50 week MA | $29.3 | 33% below |
| 100 week MA | $47.7 | 59% below |
| 200 week MA | $102.9 | 81% below |
YARW is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
YARW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18,000.0 | $6,372.0 | -65% |
| 2021 | $6,372.0 | $1,008.0 | -84% |
| 2022 | $1,008.0 | $107.0 | -89% |
| 2023 | $107.0 | $116.5 | +8.9% |
| 2024 | $116.5 | $158.5 | +36% |
| 2025 | $158.5 | $29.4 | -81% |
| 2026 YTD | $29.4 | $19.6 | -33% |
YARW has finished lower in four of the last six years. It's down 33% so far in 2026.